Arrival of 20 Containers of Hemp Energy Drink in Canada

Arrival of 20 Containers of Hemp Energy Drink in Canada

Tetra Natural Health Announces The Arrival of 20 containers of Hemp Energy Drink in Canada

1.7 million cans to be distributed in Montreal, Toronto and Vancouver

OTTAWA, Ontario, April 30, 2019 (GLOBE NEWSWIRE) Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink made from hemp in the country. In the coming weeks, Tetra Natural Health will be in a position to supply the entire country from its distribution centres in Montreal (for the Quebec and Maritimes market), Toronto (for the Ontario and central Canada market) and Vancouver (for the Western Canada market).

Since the beginning of the year, Hemp Energy Drink ( has been available in many stores across Western Canada. Consumers have greatly appreciated this refreshing, low-calorie beverage with many natural ingredients that comes in three flavours: classic, mango and raspberry.

“We’re delighted that large quantities of Hemp Energy Drink have finally arrived and look forward to Canadian consumers getting a chance to have easy access to and taste this unique and refreshing beverage,” said Richard Giguère, CEO of Tetra Natural Health. “We thank Canadians for their patience, which will soon be rewarded since Hemp Energy Drink will be available in many stores across the country”.

 About Tetra Natural Health

Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp natural health products, or cannabinoids-based products authorized for sale by Health Canada. For information:

 About Tetra Bio-Pharma

Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabinoids and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information, visitez:

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For more information, please contact:

Richard Giguère
Chief Executive Officer
Tetra Natural Health

Media Contact

Daniel Granger
ACJ Communication
W. 514 840-7990
M. 514 232 1556

Charlotte Blanche
W. 514 840-1235, ext. 7772
M. 514 914-0593


Close Menu